Tottenham insider John Wenham believes the club will not offer Manchester City right-back Kwaku Oduroh a deal after his trial in north London, Football Insider report.

The Lowdown: Spurs trial

Spurs took Oduroh on trial towards the end of February, with the 19-year-old starting for the Under-23s against Leeds United at the Tottenham Hotspur Stadium.

The Ghanian, a right-back who can also play in a holding midfield role, has been on the books at City from Under-9 level and captained their Under-18 side last season.

His trial at N17 now appears to have come to an end, with the teenager recently turning out for Manchester City Under-23s against Liverpool.

The Latest: Wenham’s update

Spurs insider Wenham was quizzed on Oduroh by FI following his visit to Hotspur Way. He doesn’t think the club will offer the defender a long-term deal and feels he isn’t better than what Spurs currently have.

“I’ll be totally honest, I watched him in our game against Blackburn Under 23s and he didn’t look any better than what we already had.

“He came on trial, I understand his Man City contract does expire this summer.

“But based on what I saw from that game, I don’t think Tottenham are going to pursue this any further.

“To me, he didn’t look like an improvement on what we already had.

“They can’t actually offer him a contract until 1 July anyway, if his contract expired on 30 June.

“It’s not one I can see happening to be honest.”

The Verdict: Only time will tell…

Oduroh could have made a cut-price move to north London in the summer with his City contact expiring over the coming months, however, that doesn’t look likely.

Only time will tell if snubbing a move for the versatile full-back will be a good decision, but Spurs are well-stocked at right-back in their Under-23 squad.

Marcel Lavinier, Dermi Lusala and Kallum Cesay are all right-backs by trade coming through in north London, so perhaps that contributed to Spurs’ decision on Oduroh.

In other news: Spurs source: Talks now held over early agreement for 'excellent' gem; same agent as Sessegnon.